Early Impact of the Federally Mandated Local Wellness Policy on Physical Activity in Rural, Low-Income Elementary Schools in Colorado

E. Belansky,Nicholas J. Cutforth,E. Delong,C. Ross,S. Scarbro,Lynn Gilbert,Bridget Beatty,J. Marshall

DOI: https://doi.org/10.1057/jphp.2008.50

IF: 3.526

2009-02-02

Journal of Public Health Policy

Abstract:

What problem does this paper attempt to address?

Multimodal structural neuroimaging data unveil data-driven subtypes of treatment-resistant depression.

Federica Colombo,Federico Calesella,Beatrice Bravi,Lidia Fortaner-Uyà,Camilla Monopoli,Emma Tassi,Matteo Carminati,Raffaella Zanardi,Irene Bollettini,Sara Poletti,Paolo Brambilla,Alessandro Serretti,Eleonora Maggioni,Chiara Fabbri,Francesco Benedetti,Benedetta Vai,Colombo,F.,Calesella,F.,Bravi,B.,Fortaner-Uya,L.,Monopoli,C.,Tassi,E.,Carminati,M.,Zanardi,R.,Bollettini,I.,Poletti,S.,Brambilla,P.,Serretti,A.,Maggioni,E.,Fabbri,C.,Benedetti,F.,Vai,B.

DOI: https://doi.org/10.1101/2023.09.12.23295423

2023-09-13

MedRxiv

Abstract:Background: An estimated 30% of Major Depressive Disorder (MDD) patients exhibit resistance to conventional antidepressant treatments. Identifying reliable biomarkers of treatment-resistant depression (TRD) represents a major goal of precision psychiatry, which is hampered by the clinical and biological heterogeneity underlying MDD. Methods: To parse heterogeneity and uncover biologically-driven subtypes of MDD, we applied an unsupervised data-driven framework to stratify 102 MDD patients on their neuroimaging signature, including extracted measures of cortical thickness, grey matter volumes, and white matter fractional anisotropy. Our novel analytical pipeline integrated different machine learning algorithms to harmonize neuroimaging data, perform data dimensionality reduction, and provide a stability-based relative clustering validation. The obtained clusters were then characterized for TRD, history of childhood trauma and different profiles of depressive symptoms. Results: Our results indicated two different clusters of patients, differentiable with 67% of accuracy: 1) one cluster (n=59) was associated with a higher proportion of TRD compared to the other, and higher scores of energy-related depressive symptoms, history of childhood abuse and emotional neglect; this cluster showed a widespread reduction in cortical thickness and volumes, along with fractional anisotropy in the right superior fronto-occipital fasciculus, stria terminalis, and corpus callosum; 2) the second cluster (n=43) was associated with cognitive and affective depressive symptoms and thicker cortices and wider volumes compared to the other. Discussion: Our stratification of MDD patients based on structural neuroimaging identified clinically-relevant subgroups of TRD with specific symptomatic and childhood trauma profiles, which are informative for tailoring personalized and more effective interventions of treatment resistance.

English Else
Biotypes of major depressive disorder: Neuroimaging evidence from resting-state default mode network patterns.

Sugai Liang,Wei Deng,Xiaojing Li,Andrew J Greenshaw,Qiang Wang,Mingli Li,Xiaohong Ma,Tong-Jian Bai,Qi-Jing Bo,Jun Cao,Guan-Mao Chen,Wei Chen,Chang Cheng,Yu-Qi Cheng,Xi-Long Cui,Jia Duan,Yi-Ru Fang,Qi-Yong Gong,Wen-Bin Guo,Zheng-Hua Hou,Lan Hu,Li Kuang,Feng Li,Kai-Ming Li,Yan-Song Liu,Zhe-Ning Liu,Yi-Cheng Long,Qing-Hua Luo,Hua-Qing Meng,Dai-Hui Peng,Hai-Tang Qiu,Jiang Qiu,Yue-Di Shen,Yu-Shu Shi,Tian-Mei Si,Chuan-Yue Wang,Fei Wang,Kai Wang,Li Wang,Xiang Wang,Ying Wang,Xiao-Ping Wu,Xin-Ran Wu,Chun-Ming Xie,Guang-Rong Xie,Hai-Yan Xie,Peng Xie,Xiu-Feng Xu,Hong Yang,Jian Yang,Hua Yu,Jia-Shu Yao,Shu-Qiao Yao,Ying-Ying Yin,Yong-Gui Yuan,Yu-Feng Zang,Ai-Xia Zhang,Hong Zhang,Ke-Rang Zhang,Zhi-Jun Zhang,Jing-Ping Zhao,Ru-Bai Zhou,Yi-Ting Zhou,Chao-Jie Zou,Xi-Nian Zuo,Chao-Gan Yan,Tao Li

DOI: https://doi.org/10.1016/j.nicl.2020.102514

2020-01-01

Abstract:BACKGROUND:Major depressive disorder (MDD) is heterogeneous disorder associated with aberrant functional connectivity within the default mode network (DMN). This study focused on data-driven identification and validation of potential DMN-pattern-based MDD subtypes to parse heterogeneity of the disorder. METHODS:The sample comprised 1397 participants including 690 patients with MDD and 707 healthy controls (HC) registered from multiple sites based on the REST-meta-MDD Project in China. Baseline resting-state functional magnetic resonance imaging (rs-fMRI) data was recorded for each participant. Discriminative features were selected from DMN between patients and HC. Patient subgroups were defined by K-means and principle component analysis in the multi-site datasets and validated in an independent single-site dataset. Statistical significance of resultant clustering were confirmed. Demographic and clinical variables were compared between identified patient subgroups. RESULTS:Two MDD subgroups with differing functional connectivity profiles of DMN were identified in the multi-site datasets, and relatively stable in different validation samples. The predominant dysfunctional connectivity profiles were detected among superior frontal cortex, ventral medial prefrontal cortex, posterior cingulate cortex and precuneus, whereas one subgroup exhibited increases of connectivity (hyperDMN MDD) and another subgroup showed decreases of connectivity (hypoDMN MDD). The hyperDMN subgroup in the discovery dataset had age-related severity of depressive symptoms. Patient subgroups had comparable demographic and clinical symptom variables. CONCLUSIONS:Findings suggest the existence of two neural subtypes of MDD associated with different dysfunctional DMN connectivity patterns, which may provide useful evidence for parsing heterogeneity of depression and be valuable to inform the search for personalized treatment strategies.
Identifying Subgroups of Major Depressive Disorder Using Brain Structural Covariance Networks and Mapping of Associated Clinical and Cognitive Variables

Xiao Yang,Poornima Kumar,Lisa D. Nickerson,Yue Du,Min Wang,Yayun Chen,Tao Li,Diego A. Pizzagalli,Xiaohong Ma

DOI: https://doi.org/10.1016/j.bpsgos.2021.04.006

2021-01-01

Biological Psychiatry Global Open Science

Abstract:BACKGROUND: Identifying data-driven subtypes of major depressive disorder (MDD) holds promise for parsing the heterogeneity of MDD in a neurobiologically informed way. However, limited studies have used brain structural covariance networks (SCNs) for subtyping MDD. METHODS: This study included 145 unmedicated patients with MDD and 206 demographically matched healthy control subjects, who underwent a structural magnetic resonance imaging scan and a comprehensive neurocognitive battery. Patterns of structural covariance were identified using source-based morphometry across both patients with MDD and healthy control subjects. K-means clustering algorithms were applied on dysregulated structural networks in MDD to identify potential MDD subtypes. Finally, clinical and neurocognitive measures were compared between identified subgroups to elucidate the profile of these MDD subtypes. RESULTS: Source-based morphometry across all individuals identified 28 whole-brain SCNs that encompassed the prefrontal, anterior cingulate, and orbitofrontal cortices; basal ganglia; and cerebellar, visual, and motor regions. Compared with healthy control subjects, individuals with MDD showed lower structural network integrity in three networks including default mode, ventromedial prefrontal cortical, and salience networks. Clustering analysis revealed two MDD subtypes based on the patterns of structural network abnormalities in these three networks. Further profiling revealed that patients in subtype 1 had younger age of onset and more symptom severity as well as greater deficits in cognitive performance than patients in subtype 2. CONCLUSIONS: Overall, we identified two MDD subtypes based on SCNs that differed in their clinical and cognitive profile. Our results represent a proof-of-concept framework for leveraging these large-scale SCNs to parse heterogeneity in MDD.
Prediction of antidepressant treatment response with thalamo-somatomotor functional connectivity revealed by generalizable stratification of depressed patients

Yuto Kashiwagi,Tomoki Tokuda,Yuji Takahara,Yuki Sakai,Junichiro Yoshimoto,Ayumu Yamashita,Toshinori Yoshioka,Koichi Ogawa,Go Okada,Yasumasa Okamoto,Mitsuo Kawato,Okito Yamashita

DOI: https://doi.org/10.1101/2024.05.11.593664

2024-05-14

Abstract:Major depressive disorder (MDD) is diagnosed based on symptoms and signs without relying on physical, biological, or cognitive tests. MDD patients exhibit a wide range of complex symptoms, and it is assumed that there are diverse underlying neurobiological backgrounds, possibly composed of several subtypes with relatively homogeneous biological features. Initiatives, including the Research Domain Criteria, emphasize the importance of biologically stratifying MDD patients into homogeneous subtypes using a data-driven approach while utilizing genetic, neuroscience, and cognitive information. If biomarkers can stratify MDD patients into biologically homogeneous subtypes at the first episode of depression, personalized precision medicine may be within our scope. Some pioneering studies have used resting-state functional brain connectivity (rs-FC) for stratification and predicted differential responses to various treatments for different subtypes. However, to our knowledge, little research has demonstrated reproducibility (i.e., generalizability) of stratification markers in independent validation cohorts. This issue may be due to inherent measurement and sampling biases in multi-site fMRI data, or overfitting of machine learning algorithms to discovery cohorts with small sample sizes, i.e., a lack of appropriate machine learning algorithms for generalizable stratification. To address this problem, we have constructed a multi-site, multi-disorder fMRI database with prospectively and retrospectively harmonized data from thousands of samples and proposed a hierarchical supervised/unsupervised learning strategy. In line with this strategy, our previous research first developed generalizable MDD diagnostic biomarkers using this fMRI database of MDD patients via supervised learning. The MDD diagnostic biomarker determines the importance of thousands to tens of thousands of rs-FCs across the whole brain for MDD diagnosis. In this study, we constructed stratification markers for MDD patients using unsupervised learning (Multiple co-clustering) with a subset of top-ranked rs-FCs in the MDD diagnostic biomarker. We developed a method to evaluate the clustering stability between two independent datasets as a generalization metric of stratification biomarkers. To discover stratification biomarkers with high stability across datasets, we utilized two multi-site datasets with substantial differences in data acquisition facilities and fMRI measurement protocols (Dataset-1: a dataset of 138 depressed patients obtained with a unified measurement protocol across three facilities; Dataset-2: a dataset of 181 depressed patients obtained with non-unified measurement protocols across four facilities, distinct from Dataset-1). Starting from several diagnostic biomarkers, we constructed some stratification markers and identified the stratification biomarker with the highest clustering stability between the two datasets. This stratification biomarker was based on several rs-FCs between the thalamus and the postcentral gyrus, and the MDD subgroups stratified by this biomarker showed significantly different treatment responsiveness to a selective serotonin reuptake inhibitor (SSRI). By narrowing down whole-brain rs-FCs using MDD diagnostic biomarkers and further dividing the rs-FCs using multiple co-clustering, the feature dimension was significantly reduced, thereby avoiding overfitting to the training data and successfully constructing stratification biomarkers that are highly stable between independent datasets, i.e., have generalizability. Furthermore, the correlation between MDD subgroups and antidepressant treatment response was demonstrated, suggesting the potential for achieving personalized precision medicine for MDD.

Neuroscience
Neurophysiological Stratification of Major Depressive Disorder by Distinct Trajectories

Di Chen,Xiang Wang,Valerie Voon,Yuchao Jiang,Chun-Yi Zac Lo,Linbo Wang,Chun Shen,Shitong Xiang,Shuqiao Yao,Jie Zhang,Tianye Jia,Wei Cheng,Jianfeng Feng

DOI: https://doi.org/10.1038/s44220-023-00139-4

2023-01-01

Nature Mental Health

Abstract:Major depressive disorder (MDD) has been characterized by structural abnormalities of multiple brain regions. Nevertheless, little is known about the underlying neuropathological origin of MDD, particularly based on distinct trajectories of brain atrophy. Here, using the data-driven subtype and stage inference algorithm on large case–control magnetic resonance imaging data from 3,940 individuals (1,789 patients with MDD; 2,151 healthy controls), we demonstrated three highly robust spatiotemporal MDD subtypes: subtype 1 initiates from the subgenual anterior cingulate cortex, subtype 2 starts at the hippocampus and subtype 3 begins in the superior frontal gyrus and then the orbitofrontal cortex. These subtypes also exhibited distinct clinical profiles and differing transcriptomic gene expressions. Specifically, we identified suicide risk as the characteristic symptom for the ‘anterior cingulate cortex-led’ subtype, as well as low motivation (for example, work interests) for the ‘frontal-led’ and somatic anxiety for the ‘hippocampus-led’. Distinguishable cell type-specific transcriptional signatures further indicate distinct origins of MDD subtypes. Together, our data-driven findings demonstrate different spatiotemporal trajectories of MDD subtypes, which may contribute to the potential for individualized diagnostics, suicide risk alerts and optimizing therapeutic targeting.
Clinical stratification of Major Depressive Disorder in the UK Biobank: A gene-environment-brain Topological Data Analysis

Emma Tassi,Alessandro Pigoni,Nunzio Turtulici,Federica Colombo,Lidia Fortaner-Uya,Anna Maria Bianchi,Francesco Benedetti,Chiara Fabbri,Benedetta Vai,Paolo Brambilla,Eleonora Maggioni

DOI: https://doi.org/10.1101/2024.09.19.24313867

2024-09-22

Abstract:Major depressive disorder (MDD) is a leading cause of disability worldwide, affecting over 300 million people and posing a significant burden on healthcare systems. MDD is highly heterogeneous, with variations in symptoms, treatment response, and comorbidities that could be determined by diverse etiologic mechanisms, including genetic and neural substrates, and societal factors. Characterizing MDD subtypes with distinct clinical manifestations could improve patient care through targeted personalized interventions. Recently, Topological Data Analysis (TDA) has emerged as a promising tool for identifying homogeneous subgroups of diverse medical conditions and key disease markers, reducing complex data into comprehensible representations and capturing essential dataset features. Our study applied TDA to data from the UK Biobank MDD subcohort composed of 3052 samples, leveraging genetic, environmental, and neuroimaging data to stratify MDD into clinically meaningful subtypes. TDA graphs were built from unimodal and multimodal feature sets and quantitatively compared based on their capability to predict depression severity, physical comorbidities, and treatment response outcomes. Our findings showed a key role of the environment in determining the severity of depressive symptoms. Comorbid medical conditions of MDD were best predicted by brain imaging characteristics, while brain functional patterns resulted the best predictors of treatment response profiles. Our results suggest that considering genetic, environmental, and brain characteristics is essential to characterize the heterogeneity of MDD, providing avenues for the definition of robust markers of health outcomes in MDD.
More Alike than Different: Quantifying Deviations of Brain Structure and Function in Major Depressive Disorder across Neuroimaging Modalities

Nils R. Winter,Ramona Leenings,Jan Ernsting,Kelvin Sarink,Lukas Fisch,Daniel Emden,Julian Blanke,Janik Goltermann,Nils Opel,Carlotta Barkhau,Susanne Meinert,Katharina Dohm,Jonathan Repple,Marco Mauritz,Marius Gruber,Elisabeth J. Leehr,Dominik Grotegerd,Ronny Redlich,Andreas Jansen,Igor Nenadic,Markus Nöthen,Andreas Forstner,Marcella Rietschel,Joachim Groß,Jochen Bauer,Walter Heindel,Till Andlauer,Simon Eickhoff,Tilo Kircher,Udo Dannlowski,Tim Hahn

DOI: https://doi.org/10.48550/arXiv.2112.10730

2021-12-20

Neurons and Cognition

Abstract:Introduction: Identifying neurobiological differences between patients suffering from Major Depressive Disorder (MDD) and healthy individuals has been a mainstay of clinical neuroscience for decades. However, recent meta- and mega-analyses have raised concerns regarding the replicability and clinical relevance of brain alterations in depression. Methods: Here, we systematically investigate healthy controls and MDD patients across a comprehensive range of modalities including structural magnetic resonance imaging (MRI), diffusion tensor imaging, functional task-based and resting-state MRI under near-ideal conditions. To this end, we quantify the upper bounds of univariate effect sizes, predictive utility, and distributional dissimilarity in a fully harmonized cohort of N=1,809 participants. We compare the results to an MDD polygenic risk score (PRS) and environmental variables. Results: The upper bound of the effect sizes range from partial eta squared = .004 to .017, distributions overlap between 89% and 95%, with classification accuracies ranging between 54% and 55% across neuroimaging modalities. This pattern remains virtually unchanged when considering only acutely or chronically depressed patients. Differences are comparable to those found for PRS, but substantially smaller than for environmental variables. Discussion: We provide a large-scale, multimodal analysis of univariate biological differences between MDD patients and controls and show that even under near-ideal conditions and for maximum biological differences, deviations are extremely small and similarity dominates. We sketch an agenda for a new focus of future research in biological psychiatry facilitating quantitative, theory-driven research, an emphasis on computational psychiatry and multivariate machine learning approaches, as well as the utilization of ecologically valid phenotyping.
Structural and functional features of treatment‐resistant depression: A systematic review and exploratory coordinate‐based meta‐analysis of neuroimaging studies

Alessandro Miola,Nicola Meda,Giulia Perini,Fabio Sambataro

DOI: https://doi.org/10.1111/pcn.13530

2023-01-17

Psychiatry and Clinical Neurosciences

Abstract:Objectives A third of people suffering from major depressive disorder do not experience a significant improvement in their symptoms even after adequate treatment with two different antidepressant medications. This common condition, termed treatment‐resistant depression (TRD), severely affects the quality of life of millions of people worldwide, causing long‐lasting interpersonal problems and social costs. Given its epidemiological and clinical relevance and the little consensus on whether the neurobiological underpinnings of TRD differ from treatment‐sensitive depression (TSD), we sought to highlight the convergent morphometric and functional neuroimaging correlates of TRD. Methods We systematically reviewed the published literature on structural and resting‐state functional neuroimaging of TRD compared to TSD and healthy controls (HC) and performed exploratory coordinate‐based meta‐analyses (CBMA) of significant results separately for each modality and multimodally ("all‐effects"). CBMAs were also performed for each direction and combining both directions of group contrasts. Results Out of the initial 1929 studies, only eight involving 555 participants (189 patients with TRD, 156 with TSD, and 210 HC) were included. In all‐effects CBMA, precentral/superior frontal gyrus showed a significant difference between TRD and HC. Functional and structural imaging meta‐analyses did not yield statistically significant results. A marginally significant cluster of altered intrinsic activity was found between TRD and HC in the cerebellum/pons. Conclusions Frontal, cerebellar, and brainstem functions can be involved in the pathophysiology of TRD. However, the design and heterogeneity of the (scarce) published literature hinder the generalizability of the findings. This article is protected by copyright. All rights reserved.

neurosciences,psychiatry,clinical neurology
Optimizing Antidepressant Efficacy: Generalizable Multimodal Neuroimaging Biomarkers for Prediction of Treatment Response

Xiaoyu Tong,Kanhao Zhao,Gregory A Fonzo,Hua Xie,Nancy B Carlisle,Corey Keller,Desmond J Oathes,Yvette Sheline,Charles B Nemeroff,Madhukar Trivedi,Amit Etkin,Yu Zhang

DOI: https://doi.org/10.1101/2024.04.11.24305583

2024-10-08

Abstract:Major depressive disorder (MDD) is a common and often severe condition that profoundly diminishes quality of life for individuals across ages and demographic groups. Unfortunately, current antidepressant and psychotherapeutic treatments exhibit limited efficacy and unsatisfactory response rates in a substantial number of patients. The development of effective therapies for MDD is hindered by the insufficiently understood heterogeneity within the disorder and its elusive underlying mechanisms. To address these challenges, we present a target-oriented multimodal fusion framework that robustly predicts antidepressant response by integrating structural and functional connectivity data (sertraline: R-squared = 0.31; placebo: R-squared = 0.22). Remarkably, the sertraline response biomarker is further tested on an independent escitalopram-medicated cohort of MDD patients, validating its generalizability (p = 0.01) and suggesting an overlap of psychopharmacological mechanisms across selective serotonin reuptake inhibitors. Through the model, we identify multimodal neuroimaging biomarkers of antidepressant response and observe that sertraline and placebo show distinct predictive patterns. We further decompose the overall predictive patterns into constitutive network constellations with generalizable structural-functional co-variation, which exhibit treatment-specific association with personality traits and behavioral/cognitive task performance. Our innovative and interpretable multimodal framework provides novel and reliable insights into the intricate neuropsychopharmacology of antidepressant treatment, paving the way for advances in precision medicine and development of more targeted antidepressant therapeutics.

Psychiatry and Clinical Psychology
Neuroanatomical dimensions in medication-free individuals with major depressive disorder and treatment response to SSRI antidepressant medications or placebo

Cynthia H Y Fu,Mathilde Antoniades,Guray Erus,Jose A Garcia,Yong Fan,Danilo Arnone,Stephen R Arnott,Taolin Chen,Ki Sueng Choi,Cherise Chin Fatt,Benicio N Frey,Vibe G Frokjaer,Melanie Ganz,Beata R Godlewska,Stefanie Hassel,Keith Ho,Andrew M McIntosh,Kun Qin,Susan Rotzinger,Matthew D Sacchet,Jonathan Savitz,Haochang Shou,Ashish Singh,Aleks Stolicyn,Irina Strigo,Stephen C Strother,Duygu Tosun,Teresa A Victor,Dongtao Wei,Toby Wise,Roland Zahn,Ian M Anderson,W Edward Craighead,J F William Deakin,Boadie W Dunlop,Rebecca Elliott,Qiyong Gong,Ian H Gotlib,Catherine J Harmer,Sidney H Kennedy,Gitte M Knudsen,Helen S Mayberg,Martin P Paulus,Jiang Qiu,Madhukar H Trivedi,Heather C Whalley,Chao-Gan Yan,Allan H Young,Christos Davatzikos

DOI: https://doi.org/10.1038/s44220-023-00187-w

Abstract:Major depressive disorder (MDD) is a heterogeneous clinical syndrome with widespread subtle neuroanatomical correlates. Our objective was to identify the neuroanatomical dimensions that characterize MDD and predict treatment response to selective serotonin reuptake inhibitor (SSRI) antidepressants or placebo. In the COORDINATE-MDD consortium, raw MRI data were shared from international samples (N = 1,384) of medication-free individuals with first-episode and recurrent MDD (N = 685) in a current depressive episode of at least moderate severity, but not treatment-resistant depression, as well as healthy controls (N = 699). Prospective longitudinal data on treatment response were available for a subset of MDD individuals (N = 359). Treatments were either SSRI antidepressant medication (escitalopram, citalopram, sertraline) or placebo. Multi-center MRI data were harmonized, and HYDRA, a semi-supervised machine-learning clustering algorithm, was utilized to identify patterns in regional brain volumes that are associated with disease. MDD was optimally characterized by two neuroanatomical dimensions that exhibited distinct treatment responses to placebo and SSRI antidepressant medications. Dimension 1 was characterized by preserved gray and white matter (N = 290 MDD), whereas Dimension 2 was characterized by widespread subtle reductions in gray and white matter (N = 395 MDD) relative to healthy controls. Although there were no significant differences in age of onset, years of illness, number of episodes, or duration of current episode between dimensions, there was a significant interaction effect between dimensions and treatment response. Dimension 1 showed a significant improvement in depressive symptoms following treatment with SSRI medication (51.1%) but limited changes following placebo (28.6%). By contrast, Dimension 2 showed comparable improvements to either SSRI (46.9%) or placebo (42.2%) (β = -18.3, 95% CI (-34.3 to -2.3), P = 0.03). Findings from this case-control study indicate that neuroimaging-based markers can help identify the disease-based dimensions that constitute MDD and predict treatment response.
Predicting Treatment Selections for Individuals with Major Depressive Disorder According to Functional Connectivity Subgroups

Xinyi Wang,Jiaolong Qin,Rongxin Zhu,Siqi Zhang,Shui Tian,Yurong Sun,Qiang Wang,Peng Zhao,Hao Tang,Li Wang,Tianmei Si,Zhijian Yao,Qing Lu

DOI: https://doi.org/10.1089/brain.2021.0153

2022-01-01

Brain Connectivity

Abstract:Background: Major depressive disorder (MDD) is a highly prevalent and disabling disease. Currently, patients' treatment choices depend on their clinical symptoms observed by clinicians, which are subjective. Rich evidence suggests that different functional networks' dysfunctions correspond to different intervention preferences. In this study, we aimed to develop a prediction model based on data-driven subgroups to provide treatment recommendations.Methods: All 630 participants enrolled from four sites underwent functional magnetic resonances imaging at baseline. In the discovery data set (n = 228), we first identified MDD subgroups by the hierarchical clustering method using the canonical variates of resting-state functional connectivity (FC) through canonical correlation analyses. The demographic symptom improvement and FC were compared among subgroups. The preference intervention for each subgroup was also determined. Next, we predicted the individual treatment strategy. Specifically, a patient was assigned into predefined subgroups based on FC similarities and then his/her treatment strategy was determined by the subgroups' preferred interventions.Results: Three subgroups with specific treatment recommendations were emerged, including (1) a selective serotonin reuptake inhibitors-oriented subgroup with early improvements in working and activities, (2) a stimulation-oriented subgroup with more alleviation in suicide, and (3) a selective serotonin noradrenaline reuptake inhibitors-oriented subgroup with more alleviation in hypochondriasis. Through cross-dataset testing, respectively, conducted on three testing data sets, results showed an overall accuracy of 72.83%.Conclusions: Our works revealed the correspondences between subgroups and their treatment preferences and predicted individual treatment strategy based on such correspondences. Our model has the potential to support psychiatrists in early clinical decision making for better treatment outcomes. Impact statementThis study proposes a novel framework to provide treatment recommendations by integrating resting-state functional connectivity and advanced machine learning technique in a large data set. Our data-driven approach is able to objectively and automatically cluster patients into different subgroups and recommends the optimal treatment strategies based on specific brain circuits and clinical symptoms. Our results have the potential to support psychiatrists in early clinical decision making for better treatment outcomes.
Clinical and Biological Factors Are Associated with Treatment-Resistant Depression

Massimiliano Buoli,Enrico Capuzzi,Alice Caldiroli,Alessandro Ceresa,Cecilia Maria Esposito,Cristina Posio,Anna Maria Auxilia,Martina Capellazzi,Ilaria Tagliabue,Teresa Surace,Francesca Legnani,Luisa Cirella,Martina Di Paolo,Guido Nosari,Francesco Zanelli Quarantini,Massimo Clerici,Fabrizia Colmegna,Antonios Dakanalis

DOI: https://doi.org/10.3390/bs12020034

2022-02-03

Behavioral Sciences

Abstract:Background: Treatment-resistant depression (TRD) is a debilitating condition associated with unmet clinical needs. Few studies have explored clinical characteristics and serum biomarkers associated with TRD. Aims: We investigated whether there were differences in clinical and biochemical variables between patients affected by TRD than those without. Methods: We recruited 343 patients (165 males and 178 females) consecutively hospitalized for MDD to the inpatient clinics affiliated to the Fondazione IRCCS Policlinico, Milan, Italy (n = 234), and ASST Monza, Italy (n = 109). Data were obtained through a screening of the clinical charts and blood analyses conducted during the hospitalization. Results: TRD versus non-TRD patients resulted to be older (p = 0.001), to have a longer duration of illness (p < 0.001), to be more currently treated with a psychiatric poly-therapy (p < 0.001), to have currently more severe depressive symptoms as showed by the Hamilton Depression Rating Scale (HAM-D) scores (p = 0.016), to have lower bilirubin plasma levels (p < 0.001). In addition, more lifetime suicide attempts (p = 0.035), more antidepressant treatments before the current episode (p < 0.001), and a lower neutrophil to lymphocyte ratio at borderline statistically significant level (p = 0.060) were all associated with the TRD group. Conclusion: We identified candidate biomarkers associated with TRD such as bilirubin plasma levels and NLR, to be confirmed by further studies. Moreover, TRD seems to be associated with unfavorable clinical factors such as a predisposition to suicidal behaviors. Future research should replicate these results to provide robust data in support of the identification of new targets of treatment and implementation of prevention strategies for TRD.

English Else
Dimensional subtyping of first-episode drug-naïve major depressive disorder: A multisite resting-state fMRI study

Biao Zhang,Yating Li,Yuhao Shen,Wenming Zhao,Yongqiang Yu,Jin Tang,the DIRECT Consortium

DOI: https://doi.org/10.1016/j.psychres.2023.115598

IF: 11.3

2023-11-09

Psychiatry Research

Abstract:Major depressive disorder (MDD) is a heterogeneous syndrome, and understanding its neural mechanisms is crucial for the advancement of personalized medicine. However, conventional subtyping studies often categorize MDD patients into a single subgroup, neglecting the continuous interindividual variations. This implies a pressing need for a dimensional approach. 230 first-episode drug-naïve MDD patients and 395 healthy controls were obtained from 5 sites via the Rest-meta-MDD project. A Bayesian model was used to decompose the resting-state functional connectivity (RSFC) into multiple distinct RSFC patterns (refer to as "factors"), and each individual was allowed to express multiple factors to varying degrees (dimensional subtyping). The associations between demographic and clinical variables with the identified factors were calculated. We identified three latent factors with distinct but partially overlapping hypo- and hyper-RSFC patterns. Most participants co-expressed multiple latent factors. All factors shared abnormal RSFC involving the default mode network and frontoparietal network, but the directionality partially differed across factors. All factors were not significantly associated with demographic and clinical variables. These findings shed light on the interindividual variability in MDD and could form the basis for developing novel therapeutic approaches that capitalize on the heterogeneity of MDD.

psychiatry
Characterizing the distinct imaging phenotypes, clinical behavior, and genetic vulnerability of brain maturational subtypes in mood disorders

Junjie Zheng,Xiaofen Zong,Lili Tang,Huiling Guo,Pengfei Zhao,Fay Y. Womer,Xizhe Zhang,Yanqing Tang,Fei Wang

DOI: https://doi.org/10.1017/s0033291724000886

IF: 10.592

2024-05-30

Psychological Medicine

Abstract:Background Mood disorders are characterized by great heterogeneity in clinical manifestation. Uncovering such heterogeneity using neuroimaging-based individual biomarkers, clinical behaviors, and genetic risks, might contribute to elucidating the etiology of these diseases and support precision medicine. Methods We recruited 174 drug-naïve and drug-free patients with major depressive disorder and bipolar disorder, as well as 404 healthy controls. T1 MRI imaging data, clinical symptoms, and neurocognitive assessments, and genetics were obtained and analyzed. We applied regional gray matter volumes (GMV) and quantile normative modeling to create maturation curves, and then calculated individual deviations to identify subtypes within the patients using hierarchical clustering. We compared the between-subtype differences in GMV deviations, clinical behaviors, cell-specific transcriptomic associations, and polygenic risk scores. We also validated the GMV deviations based subtyping analysis in a replication cohort. Results Two subtypes emerged: subtype 1, characterized by increased GMV deviations in the frontal cortex, cognitive impairment, a higher genetic risk for Alzheimer's disease, and transcriptionally associated with Alzheimer's disease pathways, oligodendrocytes, and endothelial cells; and subtype 2, displaying globally decreased GMV deviations, more severe depressive symptoms, increased genetic vulnerability to major depressive disorder and transcriptionally related to microglia and inhibitory neurons. The distinct patterns of GMV deviations in the frontal, cingulate, and primary motor cortices between subtypes were shown to be replicable. Conclusions Our current results provide vital links between MRI-derived phenotypes, spatial transcriptome, genetic vulnerability, and clinical manifestation, and uncover the heterogeneity of mood disorders in biological and behavioral terms.

psychiatry,psychology, clinical
Identification of depression subtypes and relevant brain regions using a data-driven approach

Tomoki Tokuda,Junichiro Yoshimoto,Yu Shimizu,Go Okada,Masahiro Takamura,Yasumasa Okamoto,Shigeto Yamawaki,Kenji Doya

DOI: https://doi.org/10.1038/s41598-018-32521-z

IF: 4.6

2018-09-20

Scientific Reports

Abstract:It is well known that depressive disorder is heterogeneous, yet little is known about its neurophysiological subtypes. In the present study, we identified neurophysiological subtypes of depression related to specific neural substrates. We performed cluster analysis for 134 subjects (67 depressive subjects and 67 controls) using a high-dimensional dataset consisting of resting state functional connectivity measured by functional MRI, clinical questionnaire scores, and various biomarkers. Applying a newly developed, multiple co-clustering method to this dataset, we identified three subtypes of depression that are characterized by functional connectivity between the right Angular Gyrus (AG) and other brain areas in default mode networks, and Child Abuse Trauma Scale (CATS) scores. These subtypes are also related to Selective Serotonin-Reuptake Inhibitor (SSRI) treatment outcomes, which implies that we may be able to predict effectiveness of treatment based on AG-related functional connectivity and CATS.

multidisciplinary sciences
Identification of multimodal brain imaging biomarkers in first-episode drugs-naive major depressive disorder through a multi-site large-scale MRI consortium data

Peishan Dai,Yun Shi,Xiaoyan Zhou,Tong Xiong,Jialin Luo,Qiongpu Chen,Shenghui Liao,Zhongchao Huang,Xiaoping Yi

DOI: https://doi.org/10.1016/j.jad.2024.10.006

2025-01-15

Abstract:Background: Major depressive disorder (MDD) is a severe and common mental illness. The first-episode drugs-naive MDD (FEDN-MDD) patients, who have not undergone medication intervention, contribute to understanding the biological basis of MDD. Multimodal Magnetic Resonance Imaging can provide a comprehensive understanding of brain functional and structural abnormalities in MDD. However, most MDD studies use single-modal, small-scale MRI data. And several multimodal studies of MDD are limited to simple linear combinations of functional and structural features. Methods: We screened a large sample of FEDN-MDD patients and healthy controlsmultimodal MRI data. Extracting the fractional amplitude of low-frequency fluctuations (fALFF) feature from functional magnetic resonance imaging and the gray matter volume (GMV) feature from structural magnetic resonance imaging. The mCCA-jICA method was used to integrate these two modal features to investigate the functional-structural co-variation abnormalities in MDD. To validate the stability of the extracted functional-structural covariant abnormalities features, we apply them to identify FEDN-MDD patients. Results: The results show that compared to healthy controls, FEDN-MDD patients exhibit joint group-discriminative independent component and modality-specific group-discriminative independent component, suggesting functional-structural covariant abnormalities in MDD patients. Using lightGBM classifier, we achieve a classification accuracy of 99.84 %. Limitation: We use GMV and fALFF for multimodal fusion shows promise, but requires further validation with other datasets and exploration of additional multimodal features. Conclusions: This may indicate that multimodal fusion features can effectively explore information between different modalities and can accurately identify FEDN-MDD patients, suggesting their potential as multimodal brain imaging biomarkers for MDD.
Mapping Neurophysiological Subtypes of Major Depressive Disorder Using Normative Models of the Functional Connectome

Xiaoyi Sun,Jinrong Sun,Xiaowen Lu,Qiangli Dong,Liang Zhang,Wenxu Wang,Jin Liu,Qing Ma,Xiaoqin Wang,Dongtao Wei,Yuan Chen,Bangshan Liu,Chu-Chung Huang,Yanting Zheng,Yankun Wu,Taolin Chen,Yuqi Cheng,Xiufeng Xu,Qiyong Gong,Tianmei Si,Shijun Qiu,Ching-Po Lin,Jingliang Cheng,Yanqing Tang,Fei Wang,Jiang Qiu,Peng Xie,Lingjiang Li,Yong He,DIDA-MDD Working Group,Mingrui Xia

DOI: https://doi.org/10.1016/j.biopsych.2023.05.021

2023-12-15

Abstract:Background: Major depressive disorder (MDD) is a highly heterogeneous disorder that typically emerges in adolescence and can occur throughout adulthood. Studies aimed at quantitatively uncovering the heterogeneity of individual functional connectome abnormalities in MDD and identifying reproducibly distinct neurophysiological MDD subtypes across the lifespan, which could provide promising insights for precise diagnosis and treatment prediction, are still lacking. Methods: Leveraging resting-state functional magnetic resonance imaging data from 1148 patients with MDD and 1079 healthy control participants (ages 11-93), we conducted the largest multisite analysis to date for neurophysiological MDD subtyping. First, we characterized typical lifespan trajectories of functional connectivity strength based on the normative model and quantitatively mapped the heterogeneous individual deviations among patients with MDD. Then, we identified neurobiological MDD subtypes using an unsupervised clustering algorithm and evaluated intersite reproducibility. Finally, we validated the subtype differences in baseline clinical variables and longitudinal treatment predictive capacity. Results: Our findings indicated great intersubject heterogeneity in the spatial distribution and severity of functional connectome deviations among patients with MDD, which inspired the identification of 2 reproducible neurophysiological subtypes. Subtype 1 showed severe deviations, with positive deviations in the default mode, limbic, and subcortical areas and negative deviations in the sensorimotor and attention areas. Subtype 2 showed a moderate but converse deviation pattern. More importantly, subtype differences were observed in depressive item scores and the predictive ability of baseline deviations for antidepressant treatment outcomes. Conclusions: These findings shed light on our understanding of different neurobiological mechanisms underlying the clinical heterogeneity of MDD and are essential for developing personalized treatments for this disorder.
Transcriptomic profiles in major depressive disorder: the role of immunometabolic and cell-cycle-related pathways in depression with different levels of inflammation

Luca Sforzini,Moira Marizzoni,Chiara Bottanelli,Veronika Kunšteková,Valentina Zonca,Samantha Saleri,Melisa Kose,Giulia Lombardo,Nicole Mariani,Maria A. Nettis,Naghmeh Nikkheslat,Courtney Worrell,Zuzanna Zajkowska,Linda Pointon,Philip J. Cowen,Jonathan Cavanagh,Neil A. Harrison,Marco A. Riva,Valeria Mondelli,Edward T. Bullmore,the Neuroimmunology of Mood Disorders and Alzheimer's Disease (NIMA) Consortium,Annamaria Cattaneo,Carmine M. Pariante

DOI: https://doi.org/10.1038/s41380-024-02736-w

IF: 11

2024-09-14

Molecular Psychiatry

Abstract:Transcriptomic profiles are important indicators for molecular mechanisms and pathways involved in major depressive disorder (MDD) and its different phenotypes, such as immunometabolic depression. We performed whole-transcriptome and pathway analyses on 139 individuals from the observational, case-control, BIOmarkers in DEPression (BIODEP) study, 105 with MDD and 34 controls. We divided MDD participants based on levels of inflammation, as measured by serum high-sensitivity C-reactive protein (CRP), in n = 39 'not inflamed' (CRP < 1 mg/L), n = 31 with 'elevated CRP' (1–3 mg/L), and n = 35 with 'low-grade inflammation' (>3 mg/L). We performed whole-blood RNA sequencing using Illumina NextSeq 550 and statistical analyses with the Deseq2 package for R statistics (RUV-corrected) and subsequent pathway analyses with Ingenuity Pathway Analysis. Immunometabolic pathways were activated in individuals with CRP > 1 mg/L, although surprisingly the CRP 1–3 group showed stronger immune activation than the CRP > 3 group. The main pathways identified in the comparison between CRP < 1 group and controls were cell-cycle-related, which may be protective against immunometabolic abnormalities in this 'non-inflamed' depressed group. We further divided MDD participants based on exposure and response to antidepressants ( n = 47 non-responders, n = 37 responders, and n = 22 unmedicated), and identified specific immunomodulatory and neuroprotective pathways in responders (especially vs. non-responders), which could be relevant to treatment response. In further subgroup analyses, we found that the specific transcriptional profile of responders is independent of CRP levels, and that the inhibition of cell-cycle-related pathways in MDD with CRP < 1 mg/L is present only in those who are currently depressed, and not in the responders. The present study demonstrates immunometabolic and cell-cycle-related transcriptomic pathways associated with MDD and different (CRP-based and treatment-based) MDD phenotypes, while shedding light on potential molecular mechanisms that could prevent or facilitate an individual's trajectory toward immunometabolic depression and/or treatment-non-responsive depression. The recognition and integration of these mechanisms will facilitate a precision-medicine approach in MDD.

biochemistry & molecular biology,neurosciences,psychiatry
Data-driven biological subtypes of depression: systematic review of biological approaches to depression subtyping

Lian Beijers,Klaas J. Wardenaar,Hanna M. van Loo,Robert A. Schoevers

DOI: https://doi.org/10.1038/s41380-019-0385-5

IF: 11

2019-03-01

Molecular Psychiatry

Abstract:Research into major depressive disorder (MDD) is complicated by population heterogeneity, which has motivated the search for more homogeneous subtypes through data-driven computational methods to identify patterns in data. In addition, data on biological differences could play an important role in identifying clinically useful subtypes. This systematic review aimed to summarize evidence for biological subtypes of MDD from data-driven studies. We undertook a systematic literature search of PubMed, PsycINFO, and Embase (December 2018). We included studies that identified (1) data-driven subtypes of MDD based on biological variables, or (2) data-driven subtypes based on clinical features (e.g., symptom patterns) and validated these with biological variables post-hoc. Twenty-nine publications including 24 separate analyses in 20 unique samples were identified, including a total of ~ 4000 subjects. Five out of six biochemical studies indicated that there might be depression subtypes with and without disturbed neurotransmitter levels, and one indicated there might be an inflammatory subtype. Seven symptom-based studies identified subtypes, which were mainly determined by severity and by weight gain vs. loss. Two studies compared subtypes based on medication response. These symptom-based subtypes were associated with differences in biomarker profiles and functional connectivity, but results have not sufficiently been replicated. Four out of five neuroimaging studies found evidence for groups with structural and connectivity differences, but results were inconsistent. The single genetic study found a subtype with a distinct pattern of SNPs, but this subtype has not been replicated in an independent test sample. One study combining all aforementioned types of data discovered a subtypes with different levels of functional connectivity, childhood abuse, and treatment response, but the sample size was small. Although the reviewed work provides many leads for future research, the methodological differences across studies and lack of replication preclude definitive conclusions about the existence of clinically useful and generalizable biological subtypes.

biochemistry & molecular biology,neurosciences,psychiatry
A Neuroimaging-based Precision Medicine Framework for Depression

Yao Xiao,Fay Y. Womer,Shuai Dong,Rongxin Zhu,Ran Zhang,Jingyu Yang,Luheng Zhang,Juan Liu,Weixiong Zhang,Zhongchun Liu,Xizhe Zhang,Fei Wang

DOI: https://doi.org/10.1016/j.ajp.2023.103803

IF: 13.89

2023-10-29

Asian Journal of Psychiatry

Abstract:Background Symptom-based diagnostic criteria of depression leads to notorious heterogeneity and subjectivity. Methods The study was conducted in two stages at two sites: development of a neuroimaging-based subtyping and precise repetitive transcranial magnetic stimulation (rTMS) strategy for depression at Center 1 and its clinical application at Center 2. Center 1 identified depression subtypes and subtype-specific rTMS targets based on amplitude of low frequency fluctuation (ALFF) in a cohort of 238 major depressive disorder patients and 66 healthy controls (HC). Subtypes were identified using a Gaussian Mixture Model, and subtype-specific rTMS targets were selected based on dominant brain regions prominently differentiating depression subtypes from HC. Subsequently, one classifier was employed and 72 hospitalized, depressed youths at Center 2 received two-week precise rTMS. MRI and clinical assessments were obtained at baseline, midpoint, and treatment completion for evaluation. Results Two neuroimaging subtypes of depression, archetypal and atypical depression, were identified based on distinct frontal-posterior functional imbalance patterns as measured by ALFF. The dorsomedial prefrontal cortex was identified as the rTMS target for archetypal depression, and the occipital cortex for atypical depression. Following precise rTMS, ALFF alterations were normalized in both archetypal and atypical depressed youths, corresponding with symptom response of 90.00% in archetypal depression and 70.73% in atypical depression. Conclusions A precision medicine framework for depression was developed based on objective neurobiomarkers and implemented with promising results, actualizing a subtyping-treatment-evaluation closed loop in depression. Future randomized controlled trials are warranted.

psychiatry

Early Impact of the Federally Mandated Local Wellness Policy on Physical Activity in Rural, Low-Income Elementary Schools in Colorado

Multimodal structural neuroimaging data unveil data-driven subtypes of treatment-resistant depression.

Biotypes of major depressive disorder: Neuroimaging evidence from resting-state default mode network patterns.

Identifying Subgroups of Major Depressive Disorder Using Brain Structural Covariance Networks and Mapping of Associated Clinical and Cognitive Variables

Prediction of antidepressant treatment response with thalamo-somatomotor functional connectivity revealed by generalizable stratification of depressed patients

Neurophysiological Stratification of Major Depressive Disorder by Distinct Trajectories

Clinical stratification of Major Depressive Disorder in the UK Biobank: A gene-environment-brain Topological Data Analysis

More Alike than Different: Quantifying Deviations of Brain Structure and Function in Major Depressive Disorder across Neuroimaging Modalities

Structural and functional features of treatment‐resistant depression: A systematic review and exploratory coordinate‐based meta‐analysis of neuroimaging studies

Optimizing Antidepressant Efficacy: Generalizable Multimodal Neuroimaging Biomarkers for Prediction of Treatment Response

Neuroanatomical dimensions in medication-free individuals with major depressive disorder and treatment response to SSRI antidepressant medications or placebo

Predicting Treatment Selections for Individuals with Major Depressive Disorder According to Functional Connectivity Subgroups

Clinical and Biological Factors Are Associated with Treatment-Resistant Depression

Dimensional subtyping of first-episode drug-naïve major depressive disorder: A multisite resting-state fMRI study

Characterizing the distinct imaging phenotypes, clinical behavior, and genetic vulnerability of brain maturational subtypes in mood disorders

Identification of depression subtypes and relevant brain regions using a data-driven approach

Identification of multimodal brain imaging biomarkers in first-episode drugs-naive major depressive disorder through a multi-site large-scale MRI consortium data

Mapping Neurophysiological Subtypes of Major Depressive Disorder Using Normative Models of the Functional Connectome

Transcriptomic profiles in major depressive disorder: the role of immunometabolic and cell-cycle-related pathways in depression with different levels of inflammation

Data-driven biological subtypes of depression: systematic review of biological approaches to depression subtyping

A Neuroimaging-based Precision Medicine Framework for Depression